| (Values in U.S. Thousands) | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -15,230 | -4,020 | 6,590 | -12,410 | -10 |
| Net Income Growth | -278.86% | -161.00% | +153.10% | -124,012.40% | +97.96% |
Renovacor Inc (RCOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Renovacor Inc. is an early'stage biotechnology company developing adeno-associated virus based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants. Renovacor Inc., formerly known as Chardan Healthcare Acquisition 2 Corp., is based in NEW YORK.
Fiscal Year End Date: 12/31